Location · Houston, TX
Clinical trials in Houston, TX
838 recruiting studies have a site in the Houston area, and 205 of them accept healthy volunteers. The area includes Pasadena, Sugar Land, The Woodlands, Katy, Pearland, Baytown and nearby cities.
838 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1/Phase 2
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
AAVantgarde Bio Srl
- Location
- Phoenix, AZ + 7 other US sites
- Eligibility basics
- Ages 8–55
- RecruitingPhase 3
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Boehringer Ingelheim
- Location
- Aurora, CO + 10 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
- Location
- Escondido, CA + 26 other US sites
- Eligibility basics
- Ages 8–18
- RecruitingPhase 1
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Merida Biosciences
- Location
- Torrance, CA + 10 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
GlaxoSmithKline
- Location
- Aventura, FL + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Expedition Therapeutics, Inc
- Location
- Phoenix, AZ + 21 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
GlaxoSmithKline
- Location
- Little Rock, AR + 10 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
GlaxoSmithKline
- Location
- Little Rock, AR + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Novo Nordisk A/S
- Location
- Gilbert, AZ + 36 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
Olympus Corporation of the Americas
- Location
- Phoenix, AZ + 10 other US sites
- Eligibility basics
- Ages 50+ · Men only
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Phoenix, AZ + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Anaheim, CA + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Biogen
- Location
- Huntsville, AL + 14 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 2
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
Protalix
- Location
- Glendale, AZ + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Neurocrine Biosciences
- Location
- Little Rock, AR + 10 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Genentech, Inc.
- Location
- Beverly Hills, CA + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Nectero EAST System Clinical Study
Nectero Medical, Inc.
- Location
- Scottsdale, AZ + 35 other US sites
- Eligibility basics
- Ages 21–85
- Recruiting
BiVACOR® Total Artificial Heart Early Feasibility Study
BiVACOR Inc.
- Location
- Phoenix, AZ + 3 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche
- Location
- Dothan, AL + 58 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 22 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Crystalys Therapeutics
- Location
- Birmingham, AL + 81 other US sites
- Eligibility basics
- Ages 18–75